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Innovative chemotherapeutic agents that are active againstMycobacterium tuberculosis (Mtb) are urgently
required to control the tuberculosis (TB) epidemic. TheMtb cell envelope has distinct (lipo)polysaccharides
and glycolipids that play a critical role inMtb survival and pathogenesis and disruption of pathways involved
in the assembly of theMtb cell envelope are the primary target of anti-tubercular agents. Here we introduce
a previously unexplored approach whereby chemical agents directly target the extracellular glycans within
the unique Mtb cell envelope, rather than the intracellular biosynthetic machinery. We designed and
synthesised multimeric boronic acids that are selectively lethal to Mtb and function by targeting these
structurally unique and essential Mtb cell envelope glycans. By tuning the number of, and distance
between, boronic acid units high selectivity to Mtb, low cytotoxicity against mammalian cells and no
observable resistance was achieved. This non-conventional approach may prevent the development of
drug-resistance and will act as a platform for the design of improved, pathogen-speciﬁc, next generation
antibiotics.Introduction
Mycobacterium tuberculosis, the causative agent of tuberculosis
(TB), is the world's leading cause of death from a single infec-
tious agent claiming the lives of 1.7 million people annually.1
The incidences of drug resistant strains ofMtb are increasing at
an alarming rate and include the emergence ofMtb strains that
are not treatable with any of the current antibiotic regimens.1
Consequently, there is an urgent need for the development of
innovative, next-generation anti-tubercular treatments that
function by distinct mechanisms compared to the current drugs
available. Mtb possesses a distinctive cell envelope that is
uniquely complex and rich in a diverse range of unusual
carbohydrates and lipids.2 The cell envelope has a fundamental
role in the pathogenesis and virulence of Mtb and provides
a highly eﬃcient permeability barrier that prevents intracellular
access to many antibiotics and severely complicates anti-
tubercular treatment regimens. The core of the Mtb cell wall
is comprised of three main components: a cross-linked pepti-
doglycan (PG) network, a highly branched arabinogalactan (AG)
with both arabinose and galactose found in the furanose form,rwick, CV4 7AL, UK. E-mail: e.fullam@
wick, Coventry, CV4 7AL, UK. E-mail: m.i.
wick, Coventry, CV4 7AL, UK
tion (ESI) available. See DOI:
Chemistry 2019and long chain (C60–90) mycolic acids.3 The outer ‘myco-
membrane’ contains a large array of distinct glycolipids and
lipoglycans that are interspersed within this core and include
phosphatidylinositol mannosides (PIMS), phthiocerol dimyco-
cerosates (PDIMs), lipomannan (LM), lipoarabinomannan
(LAM), mannose-capped LAM (ManLAM), sulfolipids and
trehalose mono- and di-mycolates (TMM, TDM).4 The nal
component of theMtb envelope is an outer capsule composed of
polysaccharides, predominantly a-glucan, and proteins.5,6
Intriguingly, many of these carbohydrates are specic to the
Mycobacterium genus and are found in unusual conformations
with distinct glycosidic linkages. Molecular pathways directly
involved in the biosynthesis of the Mtb cell envelope have
proven to be especially vulnerable to chemotherapeutic agents
and include the front-line drugs isoniazid7 and ethambutol8
and second-line drugs ethionamide7 and D-cycloserine.9,10 The
current TB drug development portfolio capitalises on validated,
druggable intracellular pathways involved in the synthesis of
mycobacterial cell envelope components and include TBA-
7371,11 BTZ043,12 PBTZ169 13 and OPC-167832 14,15 that all kill
Mtb by inhibition of arabinan biosynthesis.
The Mtb cell wall glycans are essential for its survival and
pathogenesis4,16–19 and any disruption of the macromolecular
complex can be lethal to the survival of the pathogen.12,19,20
Therefore, there is the tantalizing potential that these pathogen
specic extracellular cell envelope glycans may, themselves, be
viable therapeutic targets and aﬀord a strategy for overcoming
the intrinsic Mtb cell envelope barrier. To evaluate this idea
further (Fig. 1), we selected to develop synthetic glycan receptorsChem. Sci.
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View Article Onlinewith selectivity for Mtb glycans as they are highly tunable and
more stable under physiological conditions than biological
counterparts. We selected to exploit the boronic acid pharma-
cophore that is an established glycan-binding functional group
and forms bonds with cis 1,2 and 1,3 diols that are present in
carbohydrates and there are reports of increased, synergistic
binding aﬃnity when multiple boronic acids are placed on
a single scaﬀold.21–24 In addition, a number of boron containing
agents are compatible for use in humans with a number of FDA
approved boron-drugs in clinical use in other disease areas.25–27
We report here a new class of multimeric boronic acids
which specically kill Mtb through specic binding to Mtb cell
envelope glycans. The most active compounds selectively kill
mycobacteria over other strains of bacteria and exhibited low
cytotoxicity to a panel of human cells. Whole-cell proteomics
reveals a broad physiological stress response that does not
result in the generation of resistance. The separation distance
between the boronic acids was shown to be crucial for both
activity and selectivity and evidence for preferential binding to
Mtb associated glycans is presented. These ndings suggest that
new classes of anti-tubercular therapies based on targeting the
unique extracellular components are possible.Results and discussion
Design and synthesis of multimeric boronic acids
To explore the potential of multivalent boronic acid analogues
to selectively target Mtb glycans, we designed and synthesised
a panel of compounds (1–8) to evaluate the eﬀect of the
number and separation of boronic acids units to selectively
targetMtb glycans and killMtb. A range of compounds bearing
the glycan-targeting unit, 3-carboxy-phenyl boronic acid (3-
CPBA), were synthesised (4–8) using acid chloride or carbo-
diimide coupling with the appropriate di- or tetra-PEG
(poly(ethylene glycol)) amine to provide exibility of the
spacer group between the relative position of the boronic acid
functional groups (ESI Schemes 1–3†), giving the focused
panel shown in Fig. 2 (details provided in ESI, Schemes S1–S3
and Fig. S9–24†). Systematic variation of the distance between
the boronic acids (1.5–10 nm) was achieved using variableFig. 1 Overview of the approach used in this study. Illustration highligh
target the extracellular Mtb cell-envelope glycans. The complex Mtb cell
peptidoglycan layer. This approach has several advantages over current
impenetrable Mtb cell wall barrier and the potential avoidance of drug e
Chem. Sci.lengths of PEG (poly(ethylene glycol)) diamines (5–7).
Compound 4 had an ethyl linker as a further control, but
longer alkyl chains were not soluble. For 8, a rst generation
PAMAM (polyamidoamine) dendrimer core was synthesised
and used to generate a tetrameric boronic acid (ESI, Scheme
S3†). Systematic variation of the distance between the boronic
acids (1.6–10 nm) was achieved using variable lengths of PEG
(5–7). To ensure the boronic acids were accessible for glycan
binding the Alizarin red (ARS) assay was employed to map the
selectivity of the dimeric boronic acids against a panel of
carbohydrates and were found to retain the same aﬃnity
trends as the monomeric boronic acids (Fig. S1†).Determination of antibacterial potency
This library of glycan-targeting compounds was evaluated for
antibacterial activity using the resazurin-reduction assay28 to
determine the minimum inhibitory concentrations (MIC) (Fig. 3
and Table 1). The Gram-negative organisms Escherichia coli and
Pseudomonas putida do not display the complex cell wall glycans
of mycobacteria, and were tested alongside Mycobacterium
smegmatis, Mycobacterium bovis BCG and also against Mtb. The
monomeric boronic acids (1–3) displayed low antibacterial
potency with no selective preference for Gram-negative or
mycobacterial strains. Remarkably, exposure of the same
strains to the dimeric boronic acids 4–6, which vary in distance
between the boronic acids from 12–23 atoms (1.6–3 nm),
resulted in a dramatic decrease in the MICs (780–3100 mM
against mycobacteria, Fig. 3 and Table 1) and a corresponding
increase in selectivity for mycobacteria compared to Gram-
negative organisms. Notably, the dimeric compounds 4–6
were more eﬀective against Mtb and M. bovis BCG than the
widely used non-pathogenic model organism M. smegmatis,
which is faster growing. Compound 7, with a longer linker (10
nm) was ineﬀective, with higher MICs and loss of specicity for
mycobacteria. Multivalent presentation of boronic acids has
been reported to lead to increased binding aﬃnities,22 and the
nature and length of the linker has been demonstrated in other
studies to have a large inuence on boronic acid binding
selectivity and aﬃnity and is likely to be important here.23 The
increased activity of the shorter linkers would supportting the design of multimeric boronic acids (4–8, Fig. 2) to speciﬁcally
envelope is simpliﬁed by black and blue lines, hexagons represent the
strategies that include: no requirement for the molecule to cross the
ﬄux challenges.
This journal is © The Royal Society of Chemistry 2019
Fig. 2 Boronic acid panel. (A) Overview of synthetic approach; (B) 1–3were commercially available. 4–8were synthesised as detailed in the ESI.†
Distances indicate the boron–boron distances assuming a fully extended chain: angles of 109 and bond distances of 0.15 nm. Black circle is G1
PAMAM dendrimer.
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View Article Onlinea chelation mechanism to the cell glycans (see below for
experimental evidence of binding). The longer linkers may
prevent the boronic acids aligning to the bacteria surface to
enable chelation, as well as a having a greater entropic penalty
upon binding compared to shorter linkers, as is seen in other
multivalent systems.29,30 Compound 8, based on a 1st generation
poly(amidoamine) dendrimer, also showed mycobacterial
selectivity with similar MIC values to the dimers 4–6 (MIC 780
mM, against Mtb). These results indicate that an optimal spacer
length of 1.6–3 nm (compounds 4–6) between the two boronic
acid moieties is optimal whereas longer lengths >9 nm (7)
reduce potency.This journal is © The Royal Society of Chemistry 2019Minimal bactericidal concentrations (MBCs) were also
determined against Mtb for 4–6. The MBC data demonstrates
that these boronic acid dimers are bactericidal against actively
growing Mtb at concentrations of 6.25 mM (Table S1†).In vitro cytotoxicity
The panel of boronic acids showed no signicant cytotoxicity
against human lung A549 cells, human T-lymphocyte Jurkat cells
and human epithelial Caco-2 cells with MIC99 values above
25 mM, and no lysis or agglutination of red blood cells was
observed at concentrations as high as 25 mM supportingChem. Sci.
Fig. 3 Antimicrobial activities of boronic acid derivatives 1–8 against (A) M. smegmatis, (B) M. bovis BCG, (C) M. tuberculosis, (D) E. coli (E) P.
putida. *, not tested; # represents MIC value greater than the maximum value tested (>25 mM).
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View Article Onlinea unique mode of action against mycobacteria and a window of
activity (Table S2†). To determine if the dimeric boronic acids 4–7
were impacting surface glycans, a lectin-based hemagglutination
assay was used. This determined that these dimeric boronic acidsTable 1 Bacterial susceptibility as measured by resazurin reduction mic
MIC Mycobacteria (mM)
Mycobacterium smegmatis Mycobacterium bovis BCG My
1 12.5–25 3.13 6.2
2 12.5–25 12.5 6.2
3 25 6.25 6.2
4 3.13 0.78 1.5
5 3.13 0.78–1.56 1.5
6 3.13 0.78–1.56 1.5
7 25 >25 —
8 0.78 1.56 0.7
Chem. Sci.do not inhibit lectin (ConA) mediated agglutination, (Table S2
and Fig. S2†) providing further evidence that these dimeric
boronic acids do not target, or bind strongly to, key glycan
modications found on mammalian cells. The active dimersrotitre plate assay
MIC Gram-negative (mM)
cobacterium tuberculosis Escherichia coli Pseudomonas putida
5–12.5 25 12.5–25
5–12.5 >25 12.5–25
5 >25 25
6–3.13 >25 >25
6–3.13 >25 >25
6–3.13 >25 >25
>25 >25
8–1.56 >25 >25
This journal is © The Royal Society of Chemistry 2019
Fig. 4 Biolayer interferometry analysis of 3-carboxy boronic acid functional sensor (A) against isolated Mtb cell envelope components, (B)
structure of Mtb cell-envelope components, (C) against whole E. coli and (gamma-irradiated) Mtb cells.
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View Article Online(4–6) and tetramer 8 therefore show higher selectivity for myco-
bacteria compared to the mammalian cells tested that have
distinct cell-surface glycans.Table 2 Binding aﬃnities from BLI
Kd
PG 41 mg mL1
TDM 4 mM
TMM 12 mM
LAM 41.5 mg mL1Lack of cross-resistance between dimeric boronic acid
analogues and rifampicin and meropenem
To evaluate if the most active compounds (4–6) interacted with
the front-line anti-tubercular agent rifampicin a checkerboard
assay was used. No synergistic or antagonistic eﬀects were noted
with the sum of the fractional inhibitory index (SFIC) calculated
as 2. Mono-boronic acids have been reported as having b-lac-
tamase inhibitory activity31,32 and we therefore evaluated
boronic acid dimers 4–6 for compound interactions with the b-
lactammeropenem onMtb. The SFIC for each combination was
calculated33 and found to be 1 for compound 4 and 0.6 for
compounds 5–6 indicating no synergetic and importantly no
antagonistic action on the growth inhibition, compared to the
synergistic activity of meropenem in combination with the b-
lactamase inhibitor sulbactam with a SFIC 0.3 (Table S3†).
These observations provide evidence that the multivalent
boronic acids have a unique mechanism of action compared to
the monomeric boronic acid b-lactamase transition state
inhibitors and are not inhibitors of mycobacterial b-lactamase
targets. Guided by the above results, we attempted to obtainThis journal is © The Royal Society of Chemistry 2019resistant mutants of M. bovis BCG when plating on 5 MIC
compound 5 but were unable to obtain mutants over a period of
3 months. This can be indicative that these dimeric compounds
have a multifaceted mode of action. A low level of resistance has
been found for antibiotics that target cell wall precursors
including vancomycin, which took over 30 years for resistance
to occur,34 and the newly discovered texiobactin.35Identication of Mtb glycans as targets of dimeric boronic
acids
To probe the selectivity and aﬃnity of the boronic acids towards
Mtb glycans biolayer interferometry (BLI) was employed (Fig. 4).
A biotinylated boronic acid was synthesised (Scheme S4†) and
immobilised onto streptavidin functionalised sensors to
generate a multivalent boronic acid surface. In controlChem. Sci.
Fig. 5 Whole cell proteomic analysis in response to 6. Bubble plots showMtb proteins that are up- or down-regulated at (A) 3 hours, (B) 24 hours
and (C) 48 hour. Venn diagrams indicate the number of proteins that are (D) up-regulated or (E) down-regulated after 3 hours (green), 24 hours
(red) or 48 hours (yellow) exposure to 6.
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View Article Onlineexperiments against dextran and galactan that do not contain
cis-diols, and are absent from theMtb cell envelope, no binding
was observed (Fig. S5†). A panel of isolated Mtb cell envelope
components (Fig. 4) (additional information in ESI Fig. S3–S5†)
were subsequently evaluated by BLI, revealing that the boronic
acids interacted strongly with Mtb components that containChem. Sci.glycans with cis-diols (Fig. 4, S3 and S4†): PG, AG, TMM, TDM,
LAM and LM. Kd values were obtained using a steady-state
model, giving values of 41 mg mL1 (PG), 4 mM (TDM), 12 mM
(TMM) and 41.5 mg mL1 (LAM) (Table 2). Despite strong
binding observed to AG we were unable to calculate the Kd value
as saturation was not reached. In comparison, weak bindingThis journal is © The Royal Society of Chemistry 2019
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View Article Onlineaﬃnity towards PIM6 (which has six mannoses decorating the
PIM unit) was observed, and very weak binding for PIM 1 + 2
(which have correspondingly lower degrees of glycosylation)
and notably, no detectable binding for isolated mycolic acid
methyl esters (MAMEs) and sulpholipid I which contains
a sulphated trehalose moiety. This is consistent with a multi-
valent interaction between cell wall components that contain
cis-diols and the boronic acid and clearly demonstrates that
boronic acids have the necessary capacity to engage with these
essential Mtb cell envelope constituents. To further determine
the origin of the specicity of the multimeric boronic acids for
mycobacterial glycans, we probed the interaction of the boronic
acid functionalised sensor with mammalian specic glycans
using GM3 (monosialodihexosylganglioside), which contains
a galactose residue in the pyranose conformation linked to
a terminal sialic acid moiety, and no detectable binding was
observed (Fig. S6†). Whole E. coli and (gamma-irradiated) Mtb
cells were evaluated by BLI for binding to the boronic acid
functionalised sensors. Mtb gave signicantly faster rates and
extent of binding compared to E. coli (Fig. 4C). To evaluate this
further, we investigated the interaction of lipopolysaccharide
(LPS) from E. coli, which is a major cell wall component located
on the outer membrane of Gram-negative organisms, by BLI
and weak binding was observed (Fig. S6†), consistent with the
observed interactions of whole E. coli cells. Taken together, this
BLI data supports a hypothesis that multimeric boronic acids
selectively target mycobacterial cell wall glycans that are not
found in other bacterial species or mammalian cells, leading to
the observed bactericidal activity. The lack of aﬃnity for sialic
acid terminated glycans, which features as a terminal modi-
cation on cell-surface glycans in mammalian cells may
contribute to the selectivity observed here.Global protein expression response of M. bovis BCG to
dimeric boronic acids
To gain physiological insight into the mode of action of these
multimeric boronic acids whole cell proteomics was employed.
Monoboronic acids are known to target intracellular penicillin
binding proteins, b-lactamases, proteases and tRNA synthetase
proteins31,32,36–38 and we wanted to compare and characterise the
impact of multimeric boronic acid analogues on the mycobac-
terial proteome.M. bovis BCG was exposed to 2MIC of boronic
acid dimer 6 and analysis of the whole cell protein expression
prole at 3 hours, 24 hours and 48 hours was performed. A list
for all the identied proteins, annotations and fold changes
compared to controls at each time point are in ESI List S1 (Fig. 5
and S8†).
Crucially, we detected no up- or down-regulation of peni-
cillin binding proteins, b-lactamases, proteases and tRNA
synthetase proteins (ESI List S1†) that have been previously
implicated as targets for mono-boronic acids31,32,36–38 enabling
us to rule out these intracellular targets, in-line with the mer-
openem checkerboard assays (Fig. S7 and Table S3†). Interest-
ingly, proteins from two functional groups: category 3 (cell wall
and cell processes) and category 7 (intermediary metabolism
and respiration) were particularly aﬀected, indicating that MtbThis journal is © The Royal Society of Chemistry 2019has a general stress response upon exposure of the dimeric
boronic acids. In general, we found little overlap in the proteins
that were either up- or down-regulated at the diﬀerent time
points (Fig. 5). However it was particularly notable that one
identical protein that is involved in intermediary metabolism
and respiration: Rv0560c, a putative benzoquinone methyl-
transferase that has been associated with an increase in oxygen
consumption byMtb and is an indicator of a stress response39,40
was upregulated at all time points. It is likely that chelation of
the multimeric boronic acids to the essential mycobacterial
glycans disrupts essential physiological processes that are lethal
to Mtb. Taken together the proteomics data conrms that the
multivalent presentation of boronic acids aﬀords a new route to
kill Mtb.
Conclusions
In conclusion, here we have introduced a new approach to
selectively kill Mtb by chelation of its unique cell wall glycans
using multivalent boronic acids. This is conceptually distinct
from existing drugs, which target dened intracellular pathways
and hence must also permeate the Mtb cell envelope that
confers intrinsic resistance to many antibiotics. Themultivalent
boronic acids were shown to selectively kill mycobacteria over
other bacterial species. The distance between boronic acids was
crucial with longer linkers reducing activity and selectivity. Two
boronic acid units were optimal, with a tetramer (8) showing
almost identical activity to the dimers. Biolayer interferometry
revealed strong and selective interactions with isolated Mtb
glycans and whole intact Mtb cells and whole cell proteomics
identied a broad stress response rather than a single target,
which may contribute to the lack of resistance observed. The
multimeric display of boronic acids was crucial to their mech-
anism of action and distinct function compared to analogous
monovalent boronic acids. This concept of inhibiting the
extracellular glycans on Mtb presents a unique opportunity to
develop pathogen specic agents and represents an important
step in the identication of new TB drug targets.
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